The candidate is used to treat adults with moderate-to-severe eczema - a chronic skin disorder.
The news in turn led to a fall in US rival Regeneron (NASDAQ:REGN), which shed over 5.6% to stand at $472 each.
Regeneron's drug Dupixent was approved by the US Food and Drug Administration in March this year.
Broker Jefferies said in a note that AbbVie’s mid-stage trial data for its drug, upadacitinib, seemed comparable to Dupixent’s late-stage data and the two treatments could be competitors.
Abbvie reportedly is planning a late-stage study for upadacitinib next year, and shares rose nearly 3% in late morning trading.
Abbvie shares were up 6.19% at the time of writing at $81.82 each.